A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Phase 1 Completed 41 enrolled Eli Lilly and Company Merck Sharp & Dohme LLC · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.

Timeline

Start: 2017-07-03
Primary completion: 2021-05-06
Completion: 2023-02-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Olaratumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Olaratumab	Monoclonal antibody	20 mg/kg	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Summary

Timeline

Drugs

Indications